Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Kalytera Therapeutics Inc. (V:KLY)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEDAR
Company Contact
Address: 41 Thunderbird Dr
NOVATO CA 94949-5883
Tel: N/A
Website: https://kalytera.co
IR: See website
Key People
Ronald P. Erickson
Interim Chairman of the Board
Robert E. Farrell
President, Chief Executive Officer, Director
Victoria D. Rudman
Interim Chief Financial Officer, Treasurer, Secretary
Sari Prutchi-Sagiv
Chief Scientific Officer
Moshe Yeshurun
Chief Medical Officer
 
Business Overview
Kalytera Therapeutics Inc, formerly Santa Maria Petroleum Inc. is a Canada-based company, engaged in the development of cannabinoid (CBD) therapeutics. The Company is developing CBD formulations and prodrugs to target specific disease sites within the body. The Company's development programs include Bone Fracture Healing, Osteogenesis Imperfecta, Osteoporosis and Osteoporosis in Prader-Willi syndrome (PWS). The Company is focused on the development of KAL436/9, which is a synthetic derivative of CBD that has been structurally modified to develop solubility in water to improve potency. Its KAL671 is a synthetic fatty acid amide and an endocannabinoid-like molecule that may restore bone in persons suffering from osteoporosis. The Company's researchers are exploring the ability for KAL671 to prevent bone loss in mice with genetic mutations designed to mimic aspects of PWS.
Financial Overview
For the nine months ended 30 September 2019, Kalytera Therapeutics Inc revenues was not reported. Net loss totaled $12.7M vs. income of $5.8M. Net loss reflects Impairment of Fixed Assets increase from $10.2M to $23.3M (expense), FV Adjustments of Financial Investments decrease of 93% to $901K (income), General and administrative expenses increase of 35% to $3.2M (expense).
Reporting Currency: U.S. Dollars
Enterprise value: $20.70M as of Sep 30, 2019
Annual revenue (TTM): $0.00M as of Sep 30, 2019
EBITDA (TTM): -$5.71M as of Sep 30, 2019
Net annual income (TTM): -$15.23M as of Sep 30, 2019
Free cash flow (TTM): -$9.42M as of Sep 30, 2019
Net Debt Last Fiscal Year: $3.50M as of Sep 30, 2019
Shares outstanding: 512,653,156 as of Oct 24, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization